A | B | C | D | E | F | G | H | I | J | K | L | O | P | Q | R | S | T | V | W | X | Y | Z | AA | AB | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | SAR443820 Info Trial (Europe) | SAR443820 Info Trial (Europe) | |||||||||||||||||||||||
2 | SolvingMS.org MS Research Database | https://SolvingMS.org | As of: | 6/5/2023 | |||||||||||||||||||||
3 | MS Trial Finder - Enroll in Recruiting Trials! | Calculations for Overall Score | |||||||||||||||||||||||
4 | Scroll down for heading definitions | Copyright © 2023 Solving MS - All Rights Reserved | |||||||||||||||||||||||
5 | 1 | Trial Name | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | |||||||||||||
6 | # | Overall Score | Click for Research Profile & Trial Enrollment Info | MS Type For Trial | EBV Rx | FDA Trial Phase | Phase Status | Years to Phase 4 | Prescribe Phase 4 | Phase Score Most Weight | Effective- ness | FDA Acceler- ation | Phase Score^2 xEffectiveness +Fast Track | Trial Start | Trial End | ||||||||||
7 | 1 | 25 | Immunic, Vidofludimus Calcium | RR | Treat | 3 | Recruiting | 3 | 2026 | 3 | 2.75 | 24.75 | |||||||||||||
8 | 2 | 25 | Immunic, Vidofludimus Calcium | SP PP | Treat | 2 | Recruiting | 3 | 2026 | 3 | 2.75 | 24.75 | RR | 23 Trials | |||||||||||
9 | 3 | 24 | Atara, ATA188 | SP PP | Treat | 3 | Planned | 5 | 2028 | 2.75 | 3 | 1 | 23.6875 | SP | 12 Trials | ||||||||||
10 | 4 | 23 | BTKi Tolebrutinib | ALL | 3 | Partial Hold Jun 2022 | 2 | 2025 | 3 | 2.5 | 22.5 | PP | 12 Trials | ||||||||||||
11 | 5 | 23 | BTKi Mastinib | SP PP | 3 | Recruiting | 2 | 2025 | 3 | 2.5 | 22.5 | EBV | 10 Trials | ||||||||||||
12 | 6 | 23 | BTKi Fenebrutinib | RR PP | 3 | Recruiting | 2 | 2025 | 3 | 2.5 | 22.5 | 5 | MSC Stem Cell Trials | ||||||||||||
13 | 7 | 23 | BTKI Evobrutinib * Trials | RR | 3 | Recruiting | 4 | 2027 | 3 | 2.5 | 22.5 | 5 | EBV Vaccine Trials | ||||||||||||
14 | 8 | 23 | BTKI Remibrutinib * Trials | RR | 3 | Recruiting | 4 | 2027 | 3 | 2.5 | 22.5 | 130 | See All Therapies tab | ||||||||||||
15 | 9 | 19 | Tisch MS Center, Stem Cells | SP PP | 3 | Planned | 5 | 2028 | 2.5 | 2.5 | 3 | 18.625 | 37 | Selected to profile | |||||||||||
16 | 10 | 23 | Sanofi, Frexalimab * Info | RR | Treat | 2 | Published | 5 | 2028 | 2.75 | 3 | 22.6875 | |||||||||||||
17 | 10 | 19 | Clene, CNM-Au8 nanogold * Info | RR | 2 | Completed | 5 | 2028 | 2.5 | 3 | 18.75 | ||||||||||||||
18 | 11 | 12 | Clene, CNM-Au8 nanogold * Info | SP PP | 2 | Recruiting | 7 | 2030 | 2 | 3 | 12 | ||||||||||||||
19 | 12 | 16 | BTKI Orelabrutinib * Trials | RR | 2 | Pattal Hold Dec 26 2022 | 5 | 2028 | 2.5 | 2.5 | 15.625 | 15 | Profiles completed | ||||||||||||
20 | 13 | 16 | Brainstorm, Nurown Stem Cells | SP PP | 2 | Published | 5.5 | 2029 | 2.5 | 2.5 | 15.625 | ||||||||||||||
21 | 14 | 14 | Octopus MS UK, Metformin, ALA Trial | SP | 3 | Recruiting | 5 | 2028 | 3 | 1.5 | 13.5 | ||||||||||||||
22 | 15 | 13 | Geneuro, Temelimab | RR | 2 | Published | 5.5 | 2029 | 2.5 | 2 | 12.5 | ||||||||||||||
23 | 16 | 12 | Nervgen, NVG-291 | RR | 2 | Q1 2024 | 7.5 | 2031 | 2 | 3 | 12 | ||||||||||||||
24 | 17 | 10 | Antivirals for EBV in MS | ALL | Treat | 2 | Pending | Pending funding | 2 | 2.5 | 10 | ||||||||||||||
25 | 18 | 10 | Famciclovir for EBV in MS * Trial | ALL | Treat | 2 | Recruiting or Off-label | 4 | 2027 | 2 | 2.5 | 10 | |||||||||||||
26 | 19 | 10 | Hope Biosciences, Stem Cells | RR | 2 | Recruiting or RightToTry | 6.5 | 2030 | 2 | 2.5 | 10 | ||||||||||||||
27 | 20 | 10 | Duke Univ, MSC Stem Cells * Trial | PP | 2 | Recruiting | 7 | 2030 | 2 | 2.5 | 10 | ||||||||||||||
28 | 21 | 11 | Tiziana, Foralumab * Info | SP PP | 2 | Q4 2023 | 7.5 | 2031 | 2 | 2.5 | 1 | 11 | |||||||||||||
29 | 22 | 6 | TAURUS2 Magnetic Stim Myelin Info Trial | ALL | 2 | Recruiting | 7 | 2030 | 2 | 1.5 | 6 | ||||||||||||||
30 | 23 | 6 | Metformin & AMPK | RR | 2 | Recruiting or Off-label | 7 | 2030 | 2 | 1.5 | 6 | ||||||||||||||
31 | 24 | 6 | Clemastine-Myelin Repair * Trial | RR | 2 | Recruiting or Off-label | 7 | 2030 | 2 | 1.5 | 6 | ||||||||||||||
32 | 25 | 6 | NAC (N-Acetyl Cysteine) | RR | 2 | Recruiting or OTC | 7 | 2030 | 2 | 1.5 | 6 | ||||||||||||||
33 | 26 | 8 | SAR443820 Info Trial (Europe) | RR SP | 2 | Recruiting | 7 | 2032 | 2 | 2 | 8 | 12/19/2022 | 08/27/2025 | ||||||||||||
34 | 27 | 6 | Pipeline, PIPE-307 Clemastine * Info | Treat | 2 | Recruits '22 | 7.5 | 2031 | 2 | 1.5 | 6 | ||||||||||||||
35 | 28 | 5 | MPB Tolerizing Vaccine * Trial Spain | ALL | Treat | 2 | Recruiting | 6 | 2029 | 1.5 | 2 | 4.5 | 2020 | 2024 | |||||||||||
36 | 29 | 4 | Imcyse, IMCY-0141 * Info Trial | RR | Treat | 1 | Recruiting | 8 | 2031 | 1 | 4 | 4 | |||||||||||||
37 | 30 | 3 | ImStem, Stem Cells * Info Trial | RR SP | 1 | Recruiting | 8 | 2031 | 1 | 2.5 | 2.5 | ||||||||||||||
38 | 31 | 3 | Synaptogenix, Bryostatin-1 * Info | RR | 1 | Planned | 8.5 | 2032 | 1 | 3 | 3 | ||||||||||||||
39 | 32 | 2 | Anokion MS Vaccine * Trial Info | RR | Treat | 1 | Recruiting | 7.5 | 2031 | 1 | 2 | 2 | |||||||||||||
40 | 33 | 2 | Moderna EBV 1195 Vaccine * Info | ALL | Treat | 1 | Recruiting | 8 | 2031 | 1 | 2 | 2 | |||||||||||||
41 | 34 | 2 | NIH, EBV MS Vaccine * Info Trial | SP PP | Prevent | 1 | Recruiting | 8 | 2031 | 1 | 2 | 2 | |||||||||||||
42 | 35 | 2 | LPX-TI641 Info | ALL | 1 | Planned July 2023 | 1 | 1 | 2 | 2 | |||||||||||||||
43 | 36 | 2 | Pasithea, MS Vaccine * Info | ALL | Treat | 0 | Published | 10 | 2033 | 0.5 | 2 | 1 | 1.5 | ||||||||||||
44 | |||||||||||||||||||||||||
45 | |||||||||||||||||||||||||
46 | Best viewed on a screen larger than a mobile phone. | ||||||||||||||||||||||||
47 | * Profiles coming soon! Link to ClinicalTrials page provided if available. | ||||||||||||||||||||||||
48 | Click any trial name for the Research Profile with full details on the therapy and links to trial enrollment. | ||||||||||||||||||||||||
49 | Before you discuss a trial with your doctor, contact the trial coordinator to see if you meet inclusion/exclusion criteria. | ||||||||||||||||||||||||
50 | Click All Therapies tab at bottom of screen for all 100+ therapies in the database. | ||||||||||||||||||||||||
52 | Click HERE to join the Solving MS research study group. Members are discussing and joining these trials! | ||||||||||||||||||||||||
53 | |||||||||||||||||||||||||
54 | Column Heading Definitions | ||||||||||||||||||||||||
55 | |||||||||||||||||||||||||
56 | 1 | Overall Score - most weight given to therapies closest to FDA approval. | |||||||||||||||||||||||
57 | Overall Score formula = Phase Score^2 xEffectiveness +FDA Acceleration | ||||||||||||||||||||||||
58 | |||||||||||||||||||||||||
59 | 2 | MS Type | |||||||||||||||||||||||
60 | RR | Trial is for Relapsing Remitting MS | |||||||||||||||||||||||
61 | SP | Trial is for Secondary Progressive MS | |||||||||||||||||||||||
62 | PP | Trial is for Primary Progressive MS | |||||||||||||||||||||||
63 | |||||||||||||||||||||||||
64 | 3 | EBV Rx - Therapy targets Epstein Barr virus, the probable cause of MS | |||||||||||||||||||||||
65 | |||||||||||||||||||||||||
66 | 4 | FDA Trial Phase | Phase Type | Years to Ph 4 from start | - Years to complete phase | = Years to Phase 4 from complete | |||||||||||||||||||
67 | 0 | Pre Clinical - Cell and animal studies | 12 | 3.5 | 8.5 | ||||||||||||||||||||
68 | 1 | Phase 1 - Test safety in 20-100 humans | 8.5 | 1 | 7.5 | ||||||||||||||||||||
69 | 2 | Phase 2 - Test effectiveness in 100-300 humans | 7.5 | 2 | 5.5 | ||||||||||||||||||||
70 | 3 | Phase 3 - Safety & effectiveness in 1000+ humans. | 5.5 | 3 | 2.5 | ||||||||||||||||||||
71 | 4 | Review - FDA review of Phase 3 to approve Phase 4 | 2.5 | 2.5 | 0 | ||||||||||||||||||||
72 | N/A | Phase 4 - Can now be prescribed & paid for by insurance | Varies | ||||||||||||||||||||||
73 | Note: Average times for trial completion. Issues such as funding delays can prolong the timeline. | ||||||||||||||||||||||||
78 | |||||||||||||||||||||||||
79 | 5 | Phase Status | |||||||||||||||||||||||
80 | |||||||||||||||||||||||||
81 | Complete - Trial phase is finished, awaiting review, publication of results, and funding for next phase | ||||||||||||||||||||||||
82 | Planned - Trial announced but recruiting has not started and there is no page yet at ClinicalTrials.org. | ||||||||||||||||||||||||
83 | Recruiting - Trial is actively enrolling, click trial name for full profile with links to contact information. | ||||||||||||||||||||||||
84 | Note: If Complete, you can contact trial coordinator to see when next phase starts. | ||||||||||||||||||||||||
85 | |||||||||||||||||||||||||
86 | 6 | Years to Phase 4 from today | |||||||||||||||||||||||
87 | |||||||||||||||||||||||||
88 | 7 | Phase 4 by - The year it is estimated to become available. | |||||||||||||||||||||||
89 | "When can I get it?" Phase 4 is when it can be prescribed | ||||||||||||||||||||||||
90 | Very important for progressed patients who don't meet inclusion criteria for trials. | ||||||||||||||||||||||||
91 | |||||||||||||||||||||||||
92 | 8 | Phase Score Most Weight | |||||||||||||||||||||||
93 | If phase = complete then add +0.5 to phase score | ||||||||||||||||||||||||
94 | |||||||||||||||||||||||||
95 | 9 | Score | for Effectiveness | ||||||||||||||||||||||
96 | 1 | Remission, allowing innate repair. | |||||||||||||||||||||||
97 | 2 | Cure, allowing innate repair. | |||||||||||||||||||||||
98 | 3 | Remission, plus extra repair mechanism. | |||||||||||||||||||||||
99 | 4 | Cure, plus extra repair mechanism. | |||||||||||||||||||||||
100 | Note: These are estimates, as actual effects may not be determined yet. | ||||||||||||||||||||||||
101 | |||||||||||||||||||||||||
102 | 10 | Score | FDA Acceleration Program - can accelerate trial completion | ||||||||||||||||||||||
103 | 1 | FDA Fast Track - Associated with animal data | |||||||||||||||||||||||
104 | 2 | Breakthrough Therapy - Associated with clinical trial data. | |||||||||||||||||||||||
105 | 3 | Expanded Access Program - Patients who don't meet inclusion criteria can join phase 3 trials. |